Lutikizumab
M20-465
Phase 3 small_molecule active
Quick answer
Lutikizumab for Hidradenitis Suppurativa is a Phase 3 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie
- Indication
- Hidradenitis Suppurativa
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active